These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33098080)

  • 1. Comparative Assessment of Non-trial Access to Investigational Medical Products in the U.S. and Japan.
    Nakada H; Folkers KM; Takashima K
    Ther Innov Regul Sci; 2021 Mar; 55(2):401-407. PubMed ID: 33098080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
    Bunnik EM; Aarts N; van de Vathorst S
    Health Policy; 2018 Sep; 122(9):977-983. PubMed ID: 29935731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
    Bunnik EM; Aarts N
    BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Where Can Patients Obtain Information on the Preapproval Access Pathway to Investigational Treatment in Japan? A Survey of Patient Advocacy Organizations' Websites.
    Nakada H; Takashima K
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):978-983. PubMed ID: 31592580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials.
    Caplan AL; Teagarden JR; Kearns L; Bateman-House AS; Mitchell E; Arawi T; Upshur R; Singh I; Rozynska J; Cwik V; Gardner SL
    J Med Ethics; 2018 Nov; 44(11):761-767. PubMed ID: 29982174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines.
    Pinxten W; Nys H; Dierickx K
    J Med Ethics; 2010 Dec; 36(12):791-4. PubMed ID: 20852303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oversight of Right-to-Try and Expanded Access Requests for Off-Trial Access to Investigational Drugs.
    Chapman CR; Eckman J; Bateman-House AS
    Ethics Hum Res; 2020 Jan; 42(1):2-13. PubMed ID: 31967412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The changing landscape of expanded access to investigational drugs for patients with unmet medical needs: ethical implications.
    Bunnik EM; Aarts N; van de Vathorst S
    J Pharm Policy Pract; 2017; 10():10. PubMed ID: 28239479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.
    Fountzilas E; Said R; Tsimberidou AM
    Expert Opin Investig Drugs; 2018 Feb; 27(2):155-162. PubMed ID: 29353505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors.
    Klopfenstein M; Van Campen LE; Garnett T
    Ther Innov Regul Sci; 2015 May; 49(3):352-358. PubMed ID: 29473010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
    Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
    ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-trial access to investigational drugs in India: addressing challenges in the regulatory framework.
    Mehrotra N; Manchikanti P
    Med Law Rev; 2024 Feb; 32(1):20-41. PubMed ID: 37616571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Qualitative Interview Study on Expanded Access Clinical Trials for Compassionate Use in Japan.
    Hayashi H; Nogita T; Maeda H
    Patient Prefer Adherence; 2024; 18():1471-1479. PubMed ID: 39011090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try.
    Smith C; Stout J; Adjei AA; Buckner J; Wentworth M; Tilburt J; Master Z
    J Natl Cancer Inst; 2021 Jun; 113(6):735-741. PubMed ID: 32882030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 'false hope' argument in discussions on expanded access to investigational drugs: a critical assessment.
    Hordijk M; Vermeulen SF; Bunnik EM
    Med Health Care Philos; 2022 Dec; 25(4):693-701. PubMed ID: 35951276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ensuring Justice in Access to Investigational Neurological Drugs.
    Kearns L; Bateman-House A; Caplan A
    Semin Neurol; 2018 Oct; 38(5):583-588. PubMed ID: 30321898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conflicts of interest in research involving human beings.
    Greco D; Diniz NM
    J Int Bioethique; 2008; 19(1-2):143-54, 202-3. PubMed ID: 18664007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomics and High-Consequence Infectious Diseases: A Scoping Review of Emerging Science and Potential Ethical Issues.
    Boyce AM; Garibaldi BT
    Health Secur; 2019; 17(1):62-68. PubMed ID: 30724614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical issues on the "synthetic" phosphoethanolamine clinical trial.
    Paumgartten FJR
    Rev Assoc Med Bras (1992); 2017 May; 63(5):388-392. PubMed ID: 28724033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The patient's safety and access to experimental drugs after the termination of clinical trials: regulations and trends.
    da Silva RE; Amato AA; Sousa TDR; de Carvalho MR; Novaes MRCG
    Eur J Clin Pharmacol; 2018 Aug; 74(8):1001-1010. PubMed ID: 29754216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.